Ascendiant Capital Markets raises its price target to $22, calling the e-commerce company 'very undervalued' after a stellar Q2 performance.
FDA grants Breakthrough Therapy status for a promising new drug targeting the rare and fatal Sanfilippo Syndrome Type B.
The biotech firm secured its sixth approval for the ZORYVE franchise, expanding its dermatology treatment to children as young as two.
Shares surged over 100% in after-hours trading following a $35.6 million investment to advance a strategic mining project in Alaska.
Despite a revenue beat, the semiconductor equipment supplier's net loss and missed earnings per share estimates sent shares tumbling in after-hours trading.
New trade measure seen as a significant tailwind for domestic transport and logistics companies, boosting sector stocks.
The dilutive share offering at $1.25 per share comes just a week after the energy storage company's stock surged over 100%.
The private placement deal with an institutional investor is set to fund the development of the company's massive Tanbreez rare earth project in Greenland.